ClinicalTrials.gg
CompletedNCT00364013Updated Nov 7, 2022Results posted

PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

A Phase 3 interventional study of Panitumumab and FOLFOX regimen in Metastatic Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
3rd of 88
1,183 · median 70
Started
2006
with 5 others
Phase 3
14 of 90
2 open now
Registered
12th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 3rd largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2006, is one of 14 in phase 3, and was the 12th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Oncology
  • Cancer
  • metastatic colorectal cancer
  • EGFr
  • Panitumumab
  • Clinical Trail
  • Amgen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Man or woman at least 18 years old
  • Diagnosis of colorectal cancer
  • At least 1 uni-dimensionally of at least 20 mm per modified
  • (ECOG) performance status of 0, 1, or 2
  • Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyse Exclusion Criteria:
  • History or known presence of central nervous system (CNS) metastases
  • History of another primary cancer, except: Curatively treated in situ cervical cancer, or Curatively resected non-melanoma skin cancer, or Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before randomization
  • Prior chemotherapy or systemic therapy for the treatment of metastatic colorectal carcinoma except: fluoropyrimidine-based chemotherapy or prior fluoropyrimidine therapy administered solely for the purpose of radiosensitization
  • Prior oxaliplatin therapy
  • Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, erlotinib)
  • cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 1 year prior to randomization History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > Common terminology criteria (CTC) grade 2 [ version 3.0])
  • Peripheral sensory neuropathy with functional impairment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,183 participants (actual)

Study arms

  • Experimental
    FOLFOX + Panitumumab

    Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.

    Drug: Panitumumab · Drug: FOLFOX regimen

  • Active comparator
    FOLFOX

    Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.

    Drug: FOLFOX regimen

Interventions

  • Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.

    Also known as: Vectibix®

  • The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

    Time frame: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.

Secondary outcomes

  1. Overall Survival

    The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.

    Time frame: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.

  2. Percentage of Participants With an Objective Response

    Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.

    Time frame: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

  3. Time to Progression

    Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.

    Time frame: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

  4. Duration of Response

    Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.

    Time frame: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

  5. Number of Participants With Adverse Events (AEs)

    A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"

    Time frame: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.

07

Results

Posted Mar 28, 2014

Participant flow

First patient enrolled 23 August 2006 and last patient enrolled 01 February 2008. Participant flow data are reported as of the data cut-off date of 28 August 2009.

Participant flow — Overall Study
MilestoneFOLFOX + PanitumumabFOLFOX Alone
Started593590
Received study drug586583
Completed492495
Not completed10195
Withdrew: Ineligibility determined42
Withdrew: Adverse event43
Withdrew: Withdrawal by subject1318
Withdrew: Physician decision33
Withdrew: Lost to follow-up103
Withdrew: Protocol-specified criteria66
Withdrew: Other4147
Withdrew: Ongoing2013

Outcome measures

PrimaryProgression-free Survival

Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

Time frame:
From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
Reported as:
Median · months
Progression-free Survival
monthsWild-type KRAS - FOLFOX + PanitumumabWild-type KRAS - FOLFOXMutant KRAS - FOLFOX + PanitumumabMutant KRAS - FOLFOX
Progression-free Survival9.6 (9.2 to 11.1)8.0 (7.5 to 9.3)7.3 (6.3 to 8.0)8.8 (7.7 to 9.4)
Statistical analysis
  • Wild-type KRAS - FOLFOX + Panitumumab vs Wild-type KRAS - FOLFOX · Stratified log-rank test · p = 0.0234 (P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).) · Normal score: -2.27A normal score \<0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer progression-free survival time.
  • Mutant KRAS - FOLFOX + Panitumumab vs Mutant KRAS - FOLFOX · Stratified log-rank test · p = 0.0227 (P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).) · Normal score: 2.28A normal score \<0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer progression-free survival time.
SecondaryOverall Survival

The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.

Time frame:
From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
Reported as:
Median · months
Overall Survival
monthsWild-type KRAS - FOLFOX + PanitumumabWild-type KRAS - FOLFOXMutant KRAS - FOLFOX + PanitumumabMutant KRAS - FOLFOX
Overall Survival23.9 (20.3 to 28.3)19.7 (17.6 to 22.6)15.5 (13.1 to 17.6)19.3 (16.5 to 21.8)
Statistical analysis
  • Wild-type KRAS - FOLFOX + Panitumumab vs Wild-type KRAS - FOLFOX · Stratified log-rank test · p = 0.0723 (cP-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).) · Normal score: -1.80A normal score \<0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer overall survival time.
  • Mutant KRAS - FOLFOX + Panitumumab vs Mutant KRAS - FOLFOX · Stratified log-rank test · p = 0.0678 (P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).) · Normal score: 1.83A normal score \<0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer overall survival time.
SecondaryPercentage of Participants With an Objective Response

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.

Time frame:
Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsWild-type KRAS - FOLFOX + PanitumumabWild-type KRAS - FOLFOXMutant KRAS - FOLFOX + PanitumumabMutant KRAS - FOLFOX
Percentage of Participants With an Objective Response55.21 (49.55 to 60.77)47.68 (42.12 to 53.28)39.53 (32.95 to 46.41)40.28 (33.61 to 47.24)
Statistical analysis
  • Wild-type KRAS - FOLFOX + Panitumumab vs Wild-type KRAS - FOLFOX · Stratified exact test · p = 0.0684 · Odds ratio (or): 1.35 · 95% CI 0.98 to 1.87The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFOX alone arm.
  • Mutant KRAS - FOLFOX + Panitumumab vs Mutant KRAS - FOLFOX · Stratified exact test · p = 0.9822 · Odds ratio (or): 0.98 · 95% CI 0.65 to 1.47The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFOX alone arm.
SecondaryTime to Progression

Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.

Time frame:
From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
Reported as:
Median · months
Time to Progression
monthsWild-type KRAS - FOLFOX + PanitumumabWild-type KRAS - FOLFOXMutant KRAS - FOLFOX + PanitumumabMutant KRAS - FOLFOX
Time to Progression10.8 (9.4 to 12.4)9.2 (7.7 to 9.9)7.5 (7.2 to 8.9)9.0 (7.7 to 9.5)
SecondaryDuration of Response

Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.

Time frame:
Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
Reported as:
Median · months
Duration of Response
monthsWild-type KRAS - FOLFOX + PanitumumabWild-type KRAS - FOLFOXMutant KRAS - FOLFOX + PanitumumabMutant KRAS - FOLFOX
Duration of Response11.1 (9.5 to 13.0)8.8 (7.8 to 9.7)7.4 (5.9 to 8.3)8.0 (6.5 to 9.5)
SecondaryNumber of Participants With Adverse Events (AEs)

A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"

Time frame:
From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsFOLFOX + PanitumumabFOLFOX Alone
Any adverse event583579
Serious adverse event262198
Leading to discontinuation of any study drug13684
Treatment-related adverse event (TRAE)581565
Serious treatment-related adverse event16289
TRAE leading to discontinuation of any study drug11763

Adverse events

Collected over The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus FOLFOX—262/585 (44.8%)577/585 (98.6%)
FOLFOX Alone—198/584 (33.9%)571/584 (97.8%)
Most frequent serious events
Showing 10 of 295
Most frequent serious events
EventPanitumumab Plus FOLFOXFOLFOX Alone
DiarrhoeaGastrointestinal disorders58/58517/584
DehydrationMetabolism and nutrition disorders20/5855/584
Intestinal obstructionGastrointestinal disorders18/58512/584
VomitingGastrointestinal disorders18/58512/584
PyrexiaGeneral disorders16/58515/584
Febrile neutropeniaBlood and lymphatic system disorders15/58514/584
Abdominal painGastrointestinal disorders14/58510/584
Pulmonary embolismRespiratory, thoracic and mediastinal disorders14/58510/584
NauseaGastrointestinal disorders12/5853/584
SepsisInfections and infestations12/5857/584
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPanitumumab Plus FOLFOXFOLFOX Alone
NeutropeniaBlood and lymphatic system disorders315/585353/584
DiarrhoeaGastrointestinal disorders349/585282/584
RashSkin and subcutaneous tissue disorders305/58539/584
NauseaGastrointestinal disorders261/585287/584
ParaesthesiaNervous system disorders180/585204/584
FatigueGeneral disorders199/585197/584
AnorexiaMetabolism and nutrition disorders199/585133/584
Dermatitis acneiformSkin and subcutaneous tissue disorders188/5852/584
VomitingGastrointestinal disorders175/585182/584
HypomagnesaemiaMetabolism and nutrition disorders175/58539/584

Baseline characteristics

Age, Continuous
Age, Continuous(years)FOLFOX + PanitumumabFOLFOX AloneTotal
Mean61.5 ± 10.160.3 ± 11.060.9 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)FOLFOX + PanitumumabFOLFOX AloneTotal
Female207232439
Male386358744
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FOLFOX + PanitumumabFOLFOX AloneTotal
White or Caucasian5305401070
Black or African American81523
Hispanic or Latino422668
Asian8412
Other5510
Geographic Region
Geographic Region(participants)FOLFOX + PanitumumabFOLFOX AloneTotal
Western Europe, Canada and Australia332329661
Rest of world261261522
KRAS Status
KRAS Status(participants)FOLFOX + PanitumumabFOLFOX AloneTotal
Wild-type KRAS325331656
Mutant KRAS221219440
Unevaluable KRAS474087
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)FOLFOX + PanitumumabFOLFOX AloneTotal
Grade 0332320652
Grade 1230238468
Grade 2312960
Grade 3000
Grade 4011
Mising/Unknown022
Primary tumor type
Primary tumor type(participants)FOLFOX + PanitumumabFOLFOX AloneTotal
Colon cancer394398792
Rectal cancer199192391
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275. PubMed 24024839 ↗
  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014 Jul;25(7):1346-1355. doi: 10.1093/annonc/mdu141. Epub 2014 Apr 8. PubMed 24718886 ↗
  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4. PubMed 20921465 ↗
  • Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015 Jul;51(10):1231-42. doi: 10.1016/j.ejca.2015.03.026. Epub 2015 May 5. PubMed 25956209 ↗
  • Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29. PubMed 31515083 ↗
  • Abdel-Rahman O. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 2019 Dec;18(4):e385-e393. doi: 10.1016/j.clcc.2019.07.005. Epub 2019 Jul 15. PubMed 31378656 ↗
  • Abdel-Rahman O. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 2019 Jun;18(2):110-115.e2. doi: 10.1016/j.clcc.2018.12.006. Epub 2018 Dec 28. PubMed 30679026 ↗
  • Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. Int J Cancer. 2019 Jul 15;145(2):576-585. doi: 10.1002/ijc.32110. Epub 2019 Jan 24. PubMed 30614531 ↗
  • Udar N, Lofton-Day C, Dong J, Vavrek D, Jung AS, Meier K, Iyer A, Slaughter R, Gutekunst K, Bach BA, Peeters M, Douillard JY. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study. J Cancer Res Clin Oncol. 2018 Oct;144(10):2001-2010. doi: 10.1007/s00432-018-2688-3. Epub 2018 Jul 17. PubMed 30019318 ↗
  • Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8. PubMed 29627309 ↗
  • Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119. PubMed 28449055 ↗
  • Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P, Canon JL, Koukakis R, Demonty G, Hechmati G, Douillard JY. Quality of life during first-line FOLFOX4+/-panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open. 2016 Mar 31;1(2):e000041. doi: 10.1136/esmoopen-2016-000041. eCollection 2016. PubMed 27843597 ↗
  • Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH, van Krieken JH. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer. 2015 Sep;51(13):1704-13. doi: 10.1016/j.ejca.2015.05.017. Epub 2015 Jun 3. PubMed 26049686 ↗
  • Weeraratne D, Chen A, Pennucci JJ, Wu CY, Zhang K, Wright J, Perez-Ruixo JJ, Yang BB, Kaliyaperumal A, Gupta S, Swanson SJ, Chirmule N, Starcevic M. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011 Nov 9;11:17. doi: 10.1186/1472-6904-11-17. PubMed 22070868 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2006 to primary completion in Aug 2009, 36 months.

Results were first posted in Mar 2014, 4 years 7 months after primary completion. A results delay was requested in Jul 2010.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 36 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2006
First posted
Aug 15, 2006
StartActual
Aug 1, 2006
Primary completionActual
Aug 1, 2009
CompletionActual
Mar 22, 2013
Results delay requested
Jul 20, 2010
Results first posted
Mar 28, 2014
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00364013
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 15, 2006
Start date
Aug 1, 2006
Primary completion
Aug 1, 2009
Completion
Mar 22, 2013
Results posted
Mar 28, 2014
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion